drugset

drugset / Trial / NCT00694941

A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)

NCT00694941 ↗

Phase 2 Completed 15 enrolled Ono Pharmaceutical Co., Ltd.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to investigate the long term safety of ALS patients taking ONO-2506PO.

Timeline

Start: 2008-06
Primary completion: 2008-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ARUNDIC ACID	Small molecule	1200 mg	—

Indications